{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:33:35Z","timestamp":1767771215201,"version":"build-2238731810"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR004419"],"award-info":[{"award-number":["UL1TR004419"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05316-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:19:30Z","timestamp":1761581970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative safety and survival outcomes of immune checkpoint inhibitors in brain metastases from lung cancer: a propensity-matched cohort study"],"prefix":"10.1007","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-0217","authenticated-orcid":false,"given":"Barbara","family":"Buccilli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-1562","authenticated-orcid":false,"given":"Joseph","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-9989","authenticated-orcid":false,"given":"Amna","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4329-5422","authenticated-orcid":false,"given":"Amir H.","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"5316_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/cncr.25416","volume":"117","author":"JSW Lind","year":"2011","unstructured":"Lind JSW, Lagerwaard FJ, Smit EF, Postmus PE, Slotman BJ, Senan S (2011) Time for reappraisal of extracranial treatment options? Cancer 117:597\u2013605. https:\/\/doi.org\/10.1002\/cncr.25416","journal-title":"Cancer"},{"key":"5316_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S1470-2045(09)70155-X","volume":"10","author":"LE Coate","year":"2009","unstructured":"Coate LE, John T, Tsao M-S, Shepherd FA (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10:1001\u20131010. https:\/\/doi.org\/10.1016\/S1470-2045(09)70155-X","journal-title":"Lancet Oncol"},{"key":"5316_CR3","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","volume":"22","author":"F Barlesi","year":"2011","unstructured":"Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, Bota S, Monnet I, Chajara A, Robinet G (2011) Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07 \u2013 01). Ann Oncol 22:2466\u20132470. https:\/\/doi.org\/10.1093\/annonc\/mdr003","journal-title":"Ann Oncol"},{"key":"5316_CR4","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","volume":"12","author":"AF Eichler","year":"2010","unstructured":"Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV (2010) EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 12:1193\u20131199. https:\/\/doi.org\/10.1093\/neuonc\/noq076","journal-title":"Neuro Oncol"},{"key":"5316_CR5","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto WA, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu C-C, Wang TJC, Bryant J, Chuong M, An Y, Chiang V, Nakano T, Aoyama H (2020) Mehta, survival in patients with brain metastases: summary report on the updated Diagnosis-Specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 38:3773\u20133784. https:\/\/doi.org\/10.1200\/JCO.20.01255","journal-title":"J Clin Oncol"},{"key":"5316_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JPS, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile Diagnosis-Specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419\u2013425. https:\/\/doi.org\/10.1200\/JCO.2011.38.0527","journal-title":"J Clin Oncol"},{"key":"5316_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP (2017) Estimating survival in patients with lung cancer and brain metastases. JAMA Oncol 3:827. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3834","journal-title":"JAMA Oncol"},{"key":"5316_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.lungcan.2014.06.001","volume":"85","author":"PJ Gray","year":"2014","unstructured":"Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM (2014) Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer 85:239\u2013244. https:\/\/doi.org\/10.1016\/j.lungcan.2014.06.001","journal-title":"Lung Cancer"},{"key":"5316_CR9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell lung Cancer, new England. J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"J Med"},{"key":"5316_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(20)30207-2","volume":"21","author":"F Barlesi","year":"2020","unstructured":"Barlesi F, Tomasini P (2020) Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Lancet Oncol 21:607\u2013608. https:\/\/doi.org\/10.1016\/S1470-2045(20)30207-2","journal-title":"Lancet Oncol"},{"key":"5316_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, \u00d6zg\u00fcro\u011flu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR (2020) Atezolizumab for First-Line treatment of PD-L1\u2013Selected patients with NSCLC. N Engl J Med 383:1328\u20131339. https:\/\/doi.org\/10.1056\/NEJMoa1917346","journal-title":"N Engl J Med"},{"key":"5316_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21037\/tlcr-22-54","volume":"11","author":"T Guo","year":"2022","unstructured":"Guo T, Chu L, Chu X, Yang X, Li Y, Zhou Y, Xu D, Zhang J, Wang S, Hu J, Chu Q, Moran T, Cho WC-S, Merrell KW, Rizzo S, Liu Y, Ni J, Zhu Z (2022) Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors. Transl Lung Cancer Res 11:173\u2013187. https:\/\/doi.org\/10.21037\/tlcr-22-54","journal-title":"Transl Lung Cancer Res"},{"key":"5316_CR13","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.jtocrr.2025.100797","volume":"6","author":"E Adib","year":"2025","unstructured":"Adib E, Nassar AH, Bou Farhat E, Tanguturi SK, Rahman RM, Haas-Kogan DA, Bi WL, Arnaout O, Wen PY, Kwiatkowski DJ, Awad MM, Aizer AA (2025) PD-L1, tumor mutational Burden, and outcomes in NSCLC with brain metastases: A brief report. JTO Clin Res Rep 6:100797. https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100797","journal-title":"JTO Clin Res Rep"},{"key":"5316_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","volume":"129","author":"L Crin\u00f2","year":"2019","unstructured":"Crin\u00f2 L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A (2019) Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 129:35\u201340. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.025","journal-title":"Lung Cancer"},{"key":"5316_CR15","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.ejca.2024.114296","volume":"211","author":"M Reck","year":"2024","unstructured":"Reck M, Ciuleanu T-E, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, Reinmuth N, Richardet E, Felip E, Menezes J, Cheng Y, Mizutani H, Zurawski B, Alexandru A, Carbone DP, Lu S, John T, Aoyama T, Grootendorst DJ, Hu N, Eccles LJ, Paz-Ares LG (2024) Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized checkmate 9LA trial. Eur J Cancer 211:114296. https:\/\/doi.org\/10.1016\/j.ejca.2024.114296","journal-title":"Eur J Cancer"},{"key":"5316_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","volume":"15","author":"M Babamohamadi","year":"2024","unstructured":"Babamohamadi M, Mohammadi N, Faryadi E, Haddadi M, Merati A, Ghobadinezhad F, Amirian R, Izadi Z, Hadjati J (2024) Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis 15:17. https:\/\/doi.org\/10.1038\/s41419-023-06391-x","journal-title":"Cell Death Dis"},{"key":"5316_CR17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2967\/jnumed.118.224170","volume":"60","author":"Y Xing","year":"2019","unstructured":"Xing Y, Chand G, Liu C, Cook GJR, O\u2019Doherty J, Zhao L, Wong NCL, Meszaros LK, Ting HH, Zhao J (2019) Early phase I study of a 99m Tc-Labeled Anti\u2013Programmed death Ligand-1 (PD-L1) Single-Domain antibody in SPECT\/CT assessment of PD-L1 expression in Non\u2013Small cell lung cancer. J Nucl Med 60:1213\u20131220. https:\/\/doi.org\/10.2967\/jnumed.118.224170","journal-title":"J Nucl Med"},{"key":"5316_CR18","doi-asserted-by":"publisher","first-page":"S460","DOI":"10.21037\/jtd.2017.12.51","volume":"10","author":"S Pakkala","year":"2018","unstructured":"Pakkala S, Owonikoko TK (2018) Immune checkpoint inhibitors in small cell lung cancer. J Thorac Dis 10:S460\u2013S467. https:\/\/doi.org\/10.21037\/jtd.2017.12.51","journal-title":"J Thorac Dis"},{"key":"5316_CR19","doi-asserted-by":"publisher","unstructured":"Podder V, Ranjan T, Margolin K, Maharaj A, Ahluwalia MS (2024) Evaluating the safety of immune checkpoint inhibitors and combination therapies in the management of brain metastases: a comprehensive Review cancers (Basel) 16:3929. https:\/\/doi.org\/10.3390\/cancers16233929","DOI":"10.3390\/cancers16233929"},{"key":"5316_CR20","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1007\/s00262-023-03498-0","volume":"72","author":"C Schmitt","year":"2023","unstructured":"Schmitt C, Hoefsmit EP, Fangmeier T, Kramer N, Kabakci C, Vera Gonz\u00e1lez J, Versluis JM, Compter A, Harrer T, Mijo\u010devi\u0107 H, Schubert S, Hundsberger T, Menzies AM, Scolyer RA, Long GV, French LE, Blank CU, Heinzerling LM (2023) Immune checkpoint inhibitor-induced neurotoxicity is not associated with Seroprevalence of neurotropic infections, cancer immunology. Immunotherapy 72:3475\u20133489. https:\/\/doi.org\/10.1007\/s00262-023-03498-0","journal-title":"Immunotherapy"},{"key":"5316_CR21","doi-asserted-by":"publisher","unstructured":"Farina A, Birzu C, Elsensohn M-H, Picca A, Mu\u00f1iz-Castrillo S, Vogrig A, Villagr\u00e1n-Garc\u00eda M, Ciano-Petersen NL, Massacesi L, Hervier B, Gu\u00e9gan S, Kramkimel N, Vano Y, Salem JE, Allenbach Y, Maisonobe T, Assaad S, Maureille A, Devic P, Weiss N, Pegat A, Maucort-Boulch D, Ricard D, Honnorat J, Psimaras D, Joubert B (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5. https:\/\/doi.org\/10.1093\/braincomms\/fcad169","DOI":"10.1093\/braincomms\/fcad169"},{"key":"5316_CR22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlh\u00e4ufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin\u00f2 L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous Non\u2013Small-Cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"5316_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O\u2019Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L (2019) Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung Cancer 128:105\u2013112. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.017","journal-title":"Lung Cancer"},{"key":"5316_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","volume":"14","author":"Y-L Wu","year":"2019","unstructured":"Wu Y-L, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu H-Y, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Baudelet C, Cai J, Chang J (2019) Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: checkmate 078 randomized phase III clinical trial. J Thorac Oncol 14:867\u2013875. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.006","journal-title":"J Thorac Oncol"},{"key":"5316_CR25","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY-S, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic Non\u2013Small-Cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"5316_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY-S, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous Non\u2013Small-Cell lung cancer. J Clin Oncol 38:1505\u20131517. https:\/\/doi.org\/10.1200\/JCO.19.03136","journal-title":"J Clin Oncol"},{"key":"5316_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/cam4.3675","volume":"10","author":"S Takamori","year":"2021","unstructured":"Takamori S, Komiya T, Powell E (2021) Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National cancer database propensity\u2010matched analysis. Cancer Med 10:923\u2013932. https:\/\/doi.org\/10.1002\/cam4.3675","journal-title":"Cancer Med"},{"key":"5316_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.24976\/Discov.Med.202335176.33","volume":"35","author":"J Song","year":"2023","unstructured":"Song J, Wang X, Zeng Z, Liang P, Zhong C, Liu A (2023) Efficacy of PD-1 inhibitors combined with Anti-Angiogenic therapy in driver gene mutation negative Non-Small-Cell lung cancer with brain metastases. Discov Med 35:321. https:\/\/doi.org\/10.24976\/Discov.Med.202335176.33","journal-title":"Discov Med"},{"key":"5316_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40164-023-00412-3","volume":"12","author":"H Wang","year":"2023","unstructured":"Wang H, Liu F, Chen X, Zhao C, Li X, Zhou C, Hu J, Chu Q, Jiang T (2023) Outcome differences between PD-1\/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases. Exp Hematol Oncol 12:56. https:\/\/doi.org\/10.1186\/s40164-023-00412-3","journal-title":"Exp Hematol Oncol"},{"key":"5316_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","volume":"101","author":"E Schapira","year":"2018","unstructured":"Schapira E, Hubbeling H, Yeap BY, Mehan WA, Shaw AT, Oh K, Gainor JF, Shih HA (2018) Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiation Oncology*Biology*Physics 101:624\u2013629. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.02.175","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"5316_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s44276-024-00041-1","volume":"2","author":"A Klein-Brill","year":"2024","unstructured":"Klein-Brill A, Amar-Farkash S, Rosenberg-Katz K, Brenner R, Becker JC, Aran D (2024) Comparative efficacy of combined CTLA-4 and PD-1 Blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study. BJC Rep 2:14. https:\/\/doi.org\/10.1038\/s44276-024-00041-1","journal-title":"BJC Rep"},{"key":"5316_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA, D\u2019Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM (2021) Hughes, small cell lung Cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:1441\u20131464. https:\/\/doi.org\/10.6004\/jnccn.2021.0058","journal-title":"J Natl Compr Canc Netw"},{"key":"5316_CR33","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-17-0351","volume":"16","author":"S Watanabe","year":"2017","unstructured":"Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K (2017) T790M-Selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-Positive Non\u2013Small cell lung cancer. Mol Cancer Ther 16:2563\u20132571. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0351","journal-title":"Mol Cancer Ther"},{"key":"5316_CR34","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C (2022) Hematologic complications of immune checkpoint inhibitors. Blood 139:3594\u20133604. https:\/\/doi.org\/10.1182\/blood.2020009016","journal-title":"Blood"},{"key":"5316_CR35","doi-asserted-by":"publisher","unstructured":"Grover S, Rahma OE, Hashemi N, Lim RM (2018) Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for Management, American society of clinical oncology educational book. 13\u201319. https:\/\/doi.org\/10.1200\/EDBK_100013","DOI":"10.1200\/EDBK_100013"},{"key":"5316_CR36","doi-asserted-by":"publisher","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, Bai L, Bian Y (2023) Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975","DOI":"10.3389\/fimmu.2023.1167975"}],"updated-by":[{"DOI":"10.1007\/s11060-025-05336-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000}}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05316-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05316-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05316-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:42Z","timestamp":1767702882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05316-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5316"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05316-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11060-025-05336-y","URL":"https:\/\/doi.org\/10.1007\/s11060-025-05336-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used de-identified, aggregated data from the TriNetX research network and does not meet the definition of human subjects research as defined by 45 CFR 46.102. As such, institutional review board (IRB) approval or involvement was not required. The research was conducted in accordance with the Declaration of Helsinki and applicable data protection regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}